News articles about Caladrius Biosciences (NASDAQ:CLBS) have trended somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Caladrius Biosciences earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 47.2531197525954 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Caladrius Biosciences (NASDAQ CLBS) traded up $0.43 during trading on Monday, hitting $3.50. 274,800 shares of the stock traded hands, compared to its average volume of 59,525. Caladrius Biosciences has a twelve month low of $2.63 and a twelve month high of $7.79.
Caladrius Biosciences (NASDAQ:CLBS) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.41. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 96.80%. analysts anticipate that Caladrius Biosciences will post -2.33 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Caladrius Biosciences (CLBS) Earning Somewhat Favorable Press Coverage, Accern Reports” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/20/caladrius-biosciences-clbs-earning-somewhat-favorable-press-coverage-accern-reports.html.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.